---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126322"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:50.973875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial

## Summary
- Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.
- Cash and marketable securities $178.8M at Dec 31, 2025, up from $97.5M.
- Closed $115M public offering of common stock and pre-funded warrants in Nov 2025.
- Initiated global adaptive Phase 3 IMPROVE-PAH study for IKT-001 in PAH; Part A (140 pts, PVR) then Part B (346 pts, 6MWD).
- Regulatory submissions in >20 countries; FAST-EU acceptance for accelerated trial approval.

## SEC filing metadata
- accession: 0001193125-26-126322
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/0001193125-26-126322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/d119328d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126322
- JSON: https://secwatch.observer/filing/0001193125-26-126322.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126322.txt

## Key facts
- Earnings Releases
  Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.
  - Period: year ended December 31, 2025
  - Net income: $48.3 million
  - EPS: $0.49 per share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/0001193125-26-126322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.